Genmab A/S (DKK)
GMAB
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range2,305.00 | 2,345.00
52-Wk Range- | -
Last Close2,334.00
Mkt Cap (m)152,136.33
Dividend yield-
ISINDK0010272202
Volume142,987.00
Exchange VenueCSE

Company Profile

Genmab A/S is a biotechnology company which creates and develops differentiated antibody therapeutics focused on the treatment of cancer. Its marketed product includes DARZALEX and Arzerra.

Key Information
Price/Earning63.17
Price/Book10.57
Price/Sales26.65
P/CF52.61
Rev Growth (3 year avg)43.49
EPS Growth (3 year avg)0.21
Operating Margin % 49.16
Net Margin %40.37
Return on Equity19.64
Debt/Equity0.01

Documents

Prospectus
en 19/07/2019
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

https://www.genmab.com

Financials

Income Statement
DKK201420152016201720182019
Revenue (m)850.391,133.041,816.122,365.443,025.145,366.00
Operating Income (m)265.18730.381,052.831,344.171,380.282,638.00
Net Income (m)301.30763.511,187.081,103.551,472.142,166.00
Basic EPS5.3513.0519.8318.1424.0334.40
Avg. Diluted Shares Outstanding (m)57.2560.7761.7762.0962.0563.64
Balance Sheet
DKK201420152016201720182019
Current Assets (m)2,766.353,667.894,897.646,059.437,433.0313,961.00
Non Current Assets (m)100.33234.66340.60543.521,027.971,183.00
Total Assets (m)2,866.683,902.555,238.246,602.948,461.0015,144.00
Current Liabilities (m)655.97414.40411.54327.12443.35938.00
Total Liabilities (m)------
Total Equity (m)2,032.943,486.724,826.706,272.198,014.3614,048.00
Cash Flows
DKK201420152016201720182019
Operating Cash Flows (m)132.67311.45327.721,588.971,014.791,326.00
Capital Expenditure (m)-75.44-135.39-33.11-88.51-477.37-111.00
Figures are quoted in DKK unless stated otherwise
-21.00 (-0.90%)
2,313.00
Last Price